State Street Corp Buys 57,943 Shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS)

State Street Corp grew its position in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) by 48.2% in the third quarter, HoldingsChannel.com reports. The fund owned 178,246 shares of the company’s stock after buying an additional 57,943 shares during the period. State Street Corp’s holdings in Corvus Pharmaceuticals were worth $941,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Point72 Asset Management L.P. acquired a new stake in Corvus Pharmaceuticals during the 2nd quarter valued at $10,855,000. Samlyn Capital LLC raised its position in shares of Corvus Pharmaceuticals by 160.7% in the second quarter. Samlyn Capital LLC now owns 6,123,021 shares of the company’s stock valued at $11,144,000 after purchasing an additional 3,774,658 shares during the period. Marshall Wace LLP acquired a new stake in shares of Corvus Pharmaceuticals during the 2nd quarter worth about $136,000. Connor Clark & Lunn Investment Management Ltd. boosted its holdings in shares of Corvus Pharmaceuticals by 64.7% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 137,031 shares of the company’s stock worth $724,000 after buying an additional 53,809 shares during the period. Finally, Cubist Systematic Strategies LLC acquired a new position in Corvus Pharmaceuticals in the 2nd quarter valued at about $44,000. Institutional investors own 46.64% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on CRVS shares. Mizuho upgraded Corvus Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Tuesday, October 22nd. HC Wainwright started coverage on shares of Corvus Pharmaceuticals in a research report on Thursday. They set a “buy” rating and a $11.00 price target on the stock. StockNews.com cut shares of Corvus Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, October 31st. LADENBURG THALM/SH SH raised their price objective on Corvus Pharmaceuticals from $12.00 to $21.00 and gave the stock a “buy” rating in a research note on Monday, September 16th. Finally, Oppenheimer increased their target price on Corvus Pharmaceuticals from $8.00 to $14.00 and gave the stock an “outperform” rating in a report on Wednesday, November 13th. One equities research analyst has rated the stock with a sell rating, four have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $12.38.

Corvus Pharmaceuticals Stock Up 1.5 %

NASDAQ:CRVS opened at $5.43 on Friday. Corvus Pharmaceuticals, Inc. has a twelve month low of $1.30 and a twelve month high of $10.00. The stock’s 50-day simple moving average is $7.72 and its 200 day simple moving average is $5.26. The firm has a market capitalization of $348.92 million, a PE ratio of -5.84 and a beta of 1.05.

Corvus Pharmaceuticals Company Profile

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.